IP Library Granted Patent US 10,711,024
Granted Patent B2
US 10,711,024 · App. 15/536,385 · Granted Jul 14, 2020

Steviol glycoside compounds, compositions for oral ingestion or use, and method for enhancing steviol glycoside solubility

Inventors: Ting Liu Carlson (Marietta, SC); Dan Gaspard (Excelsior, MN)
Assignee: Cargill, Incorporated
C07H15/256A23L2/56A23L2/60A23L27/36A23L27/88
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,711,024
App. No.
15/536,385
Granted
Jul 14, 2020
Kind
B2
Abstract

Novel steviol glycoside compounds characterized by a first group of four glucopyranose residues attached via the number 13 carbon (C13) of the steviol moiety and a second group of two or three glucopyranose residues attached via the number 19 carbon (C19) of the steviol moiety are described, and exemplified by compounds 1-4. These compounds can be present in a composition with other steviol glycosides (e.g., Reb D and Reb M) to enhance their solubilities. Accordingly, the novel compounds can facilitate the preparation of aqueous compositions having a higher concentration of steviol glycosides. A steviol glycoside composition including one or more of compounds 1-4 can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, nutraceuticals, and the like.

Claims (25)

1. Compound 1, 2, 3, or 4 according to the following structures:

2. A composition, comprising one or more of compounds 1, 2, 3, or 4 of claim 1 .

3. A composition, comprising one or more of compounds 1, 2, 3, or 4 of claim 1 at 0.05% to 5% (wt) of a total amount of steviol glycosides in the composition.

4. A composition, comprising all of compounds 1, 2, 3, and 4 of claim 1 .

5. A composition, comprising all of compounds 1, 2, 3, and 4 of claim 1 , wherein a total amount of compounds 1, 2, 3, and 4 in the composition is in the range of 0.5% to 10% (wt) of a total amount of steviol glycosides in the composition.

6. A composition, comprising one or more of compounds 1, 2, 3, or 4 of claim 1 , further comprising a compound selected from rebaudioside M and rebaudioside D.

7. The composition of claim 6 , wherein rebaudioside M or rebaudioside D is present in an amount greater than any one of compounds 1, 2, 3, or 4.

8. The composition of claim 6 , wherein rebaudioside M or rebaudioside D is present in an amount in the range of 10 times to 500 times greater than any one of compounds 1, 2, 3, or 4.

9. The composition of claim 6 , wherein a total amount of rebaudioside M and rebaudioside D is in the range of 20 times to 200 times greater than the total amount of compounds 1, 2, 3, and 4.

10. The composition of claim 6 , wherein a total amount of rebaudioside M and rebaudioside D in the composition is 90% (wt) or greater of a total amount steviol glycosides in the composition.

11. The composition of claim 6 , wherein a total amount of rebaudioside M and rebaudioside D in the composition is 92.5% (wt) or greater of a total amount steviol glycosides in the composition.

12. The composition of claim 2 having a total steviol glycoside concentration of at least 95%.

13. The composition of claim 12 , wherein the composition is an aqueous solution having a total steviol glycoside concentration in the range of 0.05 g/L to 5 g/L.

14. The composition of claim 2 made from a fermentation process.

15. The composition of claim 14 , wherein the fermentation process comprises use of a recombinant host cell that expresses a GGPPS, an ent-copalyl diphosphate synthase (CDPS) polypeptide, a kaurene oxidase (KO) polypeptide, a kaurene synthase (KS) polypeptide; a steviol synthase (KAH) polypeptide, a cytochrome P450 reductase (CPR) polypeptide, a UGT74G1 polypeptide, a UGT76G1 polypeptide, a UGT91 d2 polypeptide, and a EUGT11 polypeptide, wherein at least one of said polypeptides is encoded by an exogenous or heterologous gene having been introduced into said cell, wherein the host cell synthesizes the one or more of compounds 1, 2, 3, or 4.

16. The composition of claim 15 , wherein the recombinant host cell is a yeast cell.

17. The composition of claim 14 that is made by subjecting a fermentation broth, a fermentation broth concentrate, or a powder of a fermentation broth to liquid chromatography.

18. A composition suitable for oral ingestion or oral use comprising one or more of the compounds 1, 2, 3, or 4 of claim 1 .

19. A beverage, comprising one or more of the compounds 1, 2, 3, or 4 of claim 1 and one or both of rebaudioside M and rebaudioside D, wherein the rebaudioside M, the rebaudioside D, or both the rebaudioside M and the rebaudioside D are present in the beverage in an amount in the range of 0.05 g/L to 1.0 g/L.

20. A beverage, comprising one or more of the compounds 1, 2, 3, or 4 of claim 1 and having a total steviol glycoside amount in the range of 0.05 g/L to 1.0 g/L.

21. A beverage, comprising one or more of the compounds 1, 2, 3, or 4 of claim 1 and having a total steviol glycoside amount in the range of 50 ppm to 1,000 ppm.

22. The beverage of claim 21 having a total steviol glycoside amount in the range of 50 ppm to 100 ppm.

23. A beverage in which any one or more of compounds 1, 2, 3, or 4 of claim 1 are present in an amount in the range of 0.001 g/L to 0.1 g/L.

24. The composition of claim 18 selected from the group consisting of beverages, beverage concentrates, powders, foodstuffs, confections, condiments, chewing gum, dairy products, sweeteners, pharmaceutical compositions, and dental compositions.

25. A method of providing or enhancing sweetness to a composition suitable for oral ingestion or oral use comprising adding one or more of the compounds 1, 2, 3, or 4 of claim 1 to a material or composition suitable for oral ingestion or use.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2019
From: CARLSON, TING LIU; GASPARD, DAN
To: CARGILL, INCORPORATED
Reel/Frame 049444/0397 →
Continuity (2)
Provisional Application 62093213 · Dec 17, 2014
Related Publication 20170362268A1 · Dec 21, 2017